Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Carbon Monoxide for Sepsis-Induced ARDS
NCT02425579Phase 1Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Apr 2015
- Primary completion
- Aug 2019
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Carbon monoxide in acute respiratory distress syndrome (ARDS) (4 cohorts), sponsored by Brigham and Women's Hospital. Primary endpoints: Number of administration associated adverse events at 60 Days and Incidence of serious adverse events at 60 Days. Started Apr 2015; status: completed.
02
Drugs
Carbon monoxide
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT02425579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02425579.